• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Confidence limits for probability of response in multistage phase II clinical trials.

作者信息

Atkinson E N, Brown B W

出版信息

Biometrics. 1985 Sep;41(3):741-4.

PMID:4074823
Abstract

Herson (1979, Biometrics 35, 775-783) has given a method for designing one-arm k-stage phase II clinical trials, which permits early termination of the trial if the treatment is apparently ineffective, while retaining acceptable levels of power and significance. This paper gives a method for calculating the confidence limits on the response proportion, conditional on a particular study design.

摘要

相似文献

1
Confidence limits for probability of response in multistage phase II clinical trials.
Biometrics. 1985 Sep;41(3):741-4.
2
Practical side of multistage clinical trials for screening new agents.
Cancer Treat Rep. 1983 Jan;67(1):71-5.
3
On the estimation of the binomial probability in multistage clinical trials.关于多阶段临床试验中二元概率的估计
Stat Med. 2004 Mar 30;23(6):881-96. doi: 10.1002/sim.1653.
4
Design and analysis of phase I clinical trials.I期临床试验的设计与分析。
Biometrics. 1989 Sep;45(3):925-37.
5
Optimal and minimax three-stage designs for phase II oncology clinical trials.肿瘤学II期临床试验的最优和极小极大三阶段设计。
Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6.
6
Designs for group sequential phase II clinical trials.成组序贯II期临床试验设计
Biometrics. 1987 Dec;43(4):865-74.
7
Predictive probability early termination plans for phase II clinical trials.II期临床试验的预测概率早期终止计划。
Biometrics. 1979 Dec;35(4):775-83.
8
A bayesian approach to the design of phase II clinical trials.一种用于II期临床试验设计的贝叶斯方法。
Biometrics. 1988 Sep;44(3):823-36.
9
Update on planning of phase II clinical trials.
Drugs Exp Clin Res. 1986;12(1-3):43-50.
10
Stochastically curtailed phase II clinical trials.随机截尾的II期临床试验。
Stat Med. 2007 Mar 30;26(7):1462-72. doi: 10.1002/sim.2653.

引用本文的文献

1
Reparametrized generalized gamma partially linear regression with application to breast cancer data.重新参数化的广义伽马部分线性回归及其在乳腺癌数据中的应用。
J Appl Stat. 2024 Apr 2;51(15):3248-3265. doi: 10.1080/02664763.2024.2337086. eCollection 2024.
2
A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy.一项关于贝伐单抗治疗全脑放疗后进展的复发性/进行性实体瘤脑转移患者的II期试验。
Cancers (Basel). 2024 Jun 4;16(11):2133. doi: 10.3390/cancers16112133.
3
Optimal futility stopping boundaries for binary endpoints.
最佳无效终止边界的二分类结局。
BMC Med Res Methodol. 2024 Mar 28;24(1):80. doi: 10.1186/s12874-024-02190-w.
4
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer.早期治疗转录谱分析作为改善HER2阳性炎性乳腺癌病理反应预测的工具。
Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113269. doi: 10.1177/17588359221113269. eCollection 2022.
5
A stochastically curtailed single-arm phase II trial design for binary outcomes.针对二分类结局的随机截尾单臂二期临床试验设计。
J Biopharm Stat. 2022 Sep 3;32(5):671-691. doi: 10.1080/10543406.2021.2009498. Epub 2022 Jan 25.
6
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.一项关于奥法木单抗联合泼尼松作为慢性移植物抗宿主病初始治疗的 2 期多中心试验。
Blood Adv. 2022 Jan 11;6(1):259-269. doi: 10.1182/bloodadvances.2021005552.
7
Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.转移性去势抵抗性前列腺癌中 c-MET 和雄激素受体的双重阻断:恩扎卢胺和克唑替尼同时治疗的 I 期研究。
Clin Cancer Res. 2020 Dec 1;26(23):6122-6131. doi: 10.1158/1078-0432.CCR-20-2306. Epub 2020 Sep 17.
8
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).免疫治疗联合替西木单抗和贝伐珠单抗在不可切除 III 期非鳞状非小细胞肺癌(NS-NSCLC)患者放化疗后的 II 期研究:ECOG-ACRIN 癌症研究组(E6508)的一项试验。
Clin Lung Cancer. 2020 Nov;21(6):520-526. doi: 10.1016/j.cllc.2020.06.007. Epub 2020 Jun 12.
9
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.瑞戈非尼用于难治性晚期胆管癌的多机构2期试验。
Cancer. 2020 Aug 1;126(15):3464-3470. doi: 10.1002/cncr.32964. Epub 2020 May 26.
10
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.阿利塞替布联合诱导化疗用于既往未治疗的高危急性髓系白血病患者:一项单臂2期试验。
Lancet Haematol. 2020 Feb;7(2):e122-e133. doi: 10.1016/S2352-3026(19)30203-0. Epub 2019 Dec 11.